Evidence map›Paper›PMID 38765240›Full record

ArticleToxicology research2024

The paradox of Picroside II: As a natural antioxidant, but may instead futher aggravate liver injury by exacerbating mitochondrial oxidative stress.

Xu Yifan, Huang Jingfeng, Zhuang Huichuan, Lin Junqian, Jiang Zhenzhou, Sun Lixin, Huang Xin, Zhang Luyong, Wang Tao

Abstract read
In one paragraph

Article in Toxicology research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xu YifanNew Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Gulou District, Nanjing, Jiangsu, 210009, China.ORCID https://orcid.org/0009-0002-3969-0443
Huang JingfengPharmacology and Toxicology Laboratory, Grand Theravac Life Science (Nanjing) Co., Ltd, 699 Xuanwu Avenue, Xuanwu District, Nanjing, Jiangsu, 210018, China.
Zhuang HuichuanDepartment of Pharmacy, Qinhuai Branch of General Hospital of Eastern Theater Command of Chinese PLA, 34, Yang Gongjing, Distrik Qinhuai, Nanjing, Jiangsu, 210001, China.
Lin JunqianNew Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Gulou District, Nanjing, Jiangsu, 210009, China.
Jiang ZhenzhouNew Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Gulou District, Nanjing, Jiangsu, 210009, China.ORCID https://orcid.org/0000-0002-0420-0822
Sun LixinNew Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Gulou District, Nanjing, Jiangsu, 210009, China.
Huang XinNew Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Gulou District, Nanjing, Jiangsu, 210009, China.
Zhang LuyongNew Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Gulou District, Nanjing, Jiangsu, 210009, China.
Wang TaoNew Drug Screening and Pharmacodynamics Evaluation Center, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Gulou District, Nanjing, Jiangsu, 210009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Picroside II (PII), an iridoid glycoside extracted from the rhizomes and stems of the genus Picroside, exhibits pronounced hepatoprotective properties. Pre-administration of PII protects against acute liver injury caused by D-galactosamine (D-Gal), carbon tetrachloride (CCl Methods: Exploring the role of PII treatment in APAP-treated cell and rat models and in D-Gal and CCl Results: In rats, APAP treatment increased serum aspartate transaminase, alanine transaminase, and alkaline phosphatase levels and decreased glutathione activity and the fluidity of the liver mitochondrial membrane. In L-02 cells, APAP exposure resulted in a decrement in membrane potential, an augmentation in the liberation of reactive oxygen species, and an acceleration of apoptotic processes. Moreover, PII pre-administration protected against D-Gal-induced acute hepatic injury and CCl Conclusions: Our results suggest that the effects of PII depend on the hepatic physiological or pathological state at the time of intervention. While PII possesses the potential to avert drug-induced acute hepatic injury through the mitigation of oxidative stress, its administration post-injury may exacerbate the hepatic damage, underscoring the critical importance of timing in therapeutic interventions.

Indexed as

AcetaminophenAcute liver injuryHepatotoxicity and hepatoprotectionMitochondriaOxidative stressPicroside II

Identifiers

PMID38765240
PMCPMC11100354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.